Effect af Vitamin D Treatment in Primary Hyperparathyroidism

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00674154
First received: May 5, 2008
Last updated: September 12, 2012
Last verified: September 2012

May 5, 2008
September 12, 2012
May 2008
April 2013   (final data collection date for primary outcome measure)
Decrease in P-PTH [ Time Frame: One year ] [ Designated as safety issue: No ]
Fall in P-PTH [ Time Frame: One year ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00674154 on ClinicalTrials.gov Archive Site
  • Improved muscular function [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Reduced postoperative hypocalcemia [ Time Frame: Postoperative week ] [ Designated as safety issue: No ]
  • Increase in quality of life [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Increased bone mineral density [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Increase in trabecular and cortical vBMD measured by QCT and pQCT of hip, spine and forearm [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Improved muscular function [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Reduced postoperative hypocalcemia [ Time Frame: Postoperative week ] [ Designated as safety issue: No ]
  • Improved quality of life [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Improved calcification of bones [ Time Frame: One year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effect af Vitamin D Treatment in Primary Hyperparathyroidism
Effect of Vitamin D Treatment in Primary Hyperparathyroidism

The primary aim of the study is to assess whether 6-months of vitamin D supplements prior to surgery decreases the risk of postoperative hypocalcaemia in patients with PHPT. Secondary endpoints include effects of vitamin D supplements on bone turnover, BMD, quality of life, overall well-being, and muscle function.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Vitamin D Deficiency
  • Primary Hyperparathyroidism
  • Hypercalcemia
Drug: Cholecalciferol
2800 IE daily in 52 weeks
Other Names:
  • cholecalciferol
  • vitamin D
  • Experimental: 1
    Cholecalciferol 1400 IE, 2 tablets once daily in 52 weeks
    Intervention: Drug: Cholecalciferol
  • Placebo Comparator: 2
    Placebo, two tablets daily in 52 weeks.
    Intervention: Drug: Cholecalciferol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
50
May 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • P-Ca-ion > 1,30 mmol/l
  • P-PTH > 5 pmol/l
  • P-OH25-vitamin D < 80 nmol/l

Exclusion Criteria:

  • P-creatinin > 120 mumol/l
  • usage of Etalpha, Mimpara
  • Cancer
  • Sarcoidosis
  • malabsorption
  • pancreatitis
  • alcohol abuse
  • pregnancy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00674154
PHPT-20080011
Yes
University of Aarhus
University of Aarhus
Not Provided
Principal Investigator: Lars Rolighed, MD
Study Director: Lars Rejnmark, MD,PhD,DrMed
University of Aarhus
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP